CTLA4 and renal cell carcinoma: Accordingly, there has been increasing interest in new immunotherapy modalities that diverge from this paradigm and could potentially improve the outcome of patients with metastatic RCC, including anticytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) antibody and antiprogrammed cell death 1 (PD‐1)/PD‐ligand 1 (PD‐L1) antibody 8.